Lundbeck/Myriad Marriage: Short But Not Sweet
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data on Alzheimer’s disease candidate Flurizan comes up short.
You may also be interested in...
Lilly's Semagacestat Is Latest Alzheimer's Drug To Fail; Is Class At Risk?
Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the firm struggles to replace future revenues that will be lost to drugs going off patent
Lilly's Semagacestat Is Latest Alzheimer's Drug To Fail; Is Class At Risk?
Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the firm struggles to replace future revenues that will be lost to drugs going off patent
Lilly To Cease Development Of Alzheimer's Drug: A Blow To The Amyloid Hypothesis?
Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent